Genpharmasec (BOM:531592) Retained Earnings : ₹0.0 Mil (As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Genpharmasec Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Genpharmasec's retained earnings for the quarter that ended in Dec. 2024 was ₹0.0 Mil.

Genpharmasec's annual retained earnings increased from Mar. 2022 (₹-48.7 Mil) to Mar. 2023 (₹-45.6 Mil) but then declined from Mar. 2023 (₹-45.6 Mil) to Mar. 2024 (₹-46.8 Mil).

Genpharmasec Retained Earnings Historical Data

The historical data trend for Genpharmasec's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genpharmasec Retained Earnings Chart

Genpharmasec Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Retained Earnings

Get a 7-Day Free Trial

0.48

-48.69

-45.57

-46.82

Genpharmasec Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-	-46.82	-	-	-

Genpharmasec Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Genpharmasec (BOM:531592) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Genpharmasec Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genpharmasec Ltd (BOM:531592) » Definitions » Retained Earnings

Traded in Other Exchanges

N/A

Address

Akurli Road, Office No. 104 and 105, 1st Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Kandivali (East), Mumbai, MH, IND, 400101

Website

https://www.genpharmasec.com

Genpharmasec Ltd is engaged in pharmaceutical activities and services. The company operates in two reportable segments namely; Diagnostic Pharma Equipment which includes pharmaceutical, medicinal, and medicated preparations, patent medicines, drugs, and herbs, and pharmaceutical, medicinal, and proprietary and industrial preparations, compounds, and articles of kinds, chemists, druggists, and chemical manufacturers. The Trading in the Securities segment of the company invests in the secondary securities market. The Diagnostic Pharma Equipment segment is the key revenue generator for the group.

Genpharmasec Headlines

No Headlines